Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.
1Department of Oncology, University of Oxford, Oxford, United Kingdom. *Corresponding Author: Connor E. Woolley, Department of Oncology, University of Oxford, Old Road Campus Research Building, ...
Amgen’s Lumakras has secured an FDA approval in combination with the drugmaker’s Vectibix for a subset of patients with metastatic colorectal cancer, marking a ...
This new option validates our combination approach to improve outcomes for patients living with advanced KRAS G12C-mutated metastatic ... compared to 2 months (1.9, 3.9) on investigator's choice ...
GuruFocus has detected 6 Warning Signs with AMGN. The decision, announced Thursday, applies to adults whose tumors carry the KRAS G12C mutation. Amgen's treatment pairs Lumakras (sotorasib ...
The combination treatment specifically targets KRAS-mutated metastatic colorectal cancer (CRC) to improve progression-free survival. The approval was based on results from CodeBreaK 300, a phase 3 ...
NEW YORK – The US Food and Drug Administration on Thursday approved Amgen's KRAS inhibitor Lumakras (sotorasib) with its EGFR monoclonal antibody Vectibix (panitumumab) for previously treated patients ...
in patients with chemorefractory KRAS G12C-mutated mCRC. Study results demonstrated that LUMAKRAS 960 mg daily plus Vectibix (n=53) showed an improved median PFS of 5.6 months (4.2, 6.3) compared to 2 ...
The FDA approved five fewer novel medicines than in 2023 while the EMA improved its tally by seven. Image credit: Shutterstock / Tamakhin Mykhailo. The US Food and Drug Administration (FDA) has ...
Lumakras and Vectibix combination approved for KRAS G12C-mutated mCRC after specific chemotherapy regimens. CodeBreaK 300 trial showed improved progression-free survival with Lumakras/Vectibix ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback